Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$IDRA looking ripe fer pick'ins
NOW UP 6%+ since firing on the GAPZ SCANNER!!!
only f.d.a. approval stands in da way now, 'Idera Pharmaceuticals, Inc. (IDRA)'
re;
IDERA PHARMACEUTICALS ANNOUNCES RESULTS FROM ILLUMINATE-301 TRIAL OF TILSOTOLIMOD + IPILIMUMAB IN ANTI-PD-1 REFRACTORY ADVANCED MELANOMA
https://ir.iderapharma.com/news-releases/news-release-details/idera-pharmaceuticals-announces-results-illuminate-301-trial
$IDRA Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/21/2021 4:11:28 PM
$IDRA
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/10/2021 5:26:13 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/10/2021 5:06:48 PM
i just sawer insider buying $IDRA & 59,500 any clues ????? buyout ?????
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SOLAND DANIEL B CHIEF OPERATING OFFICER Jun 18 Buy 1.19 50,000 59,500 78,843 Jun 21 04:10 PM
DOUGHERTY MICHAEL R Director Jun 01 Buy 1.19 85,000 101,150 133,584 Jun 03 04:10 PM
https://finviz.com/quote.ashx?t=idra&ty=c&ta=1&p=d
insider buying $50-000 shares IDRA
Bid: 1.28 Ask: 1.29 Last: 1.29 Chg ($): 0.13 Vol: 2.92M
$IDRA FIVE YR.
[ chart]www.stockscores.com/chart.asp?TickerSymbol=idra&TimeRange=1825&Interval=w&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=&Band=&avgType1=&movAvg1=&avgType2=&movAvg2=&Indicator1=None&Indicator2=None&Indicator3=None&Indicator4=None&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen[/chart]
$IDRA FIVE YR.
Read up on the filings for all the answers. Good luck and enjoy the weekend.
What is the Cash on Hand balance at IDRA? That will gve us an idea, ba esd on their monthly burn rate now, how long they have before finding a buyout or a deep pocket partner.
Workforce reduced by 50% and currently at a third of book value. It's being cleaned up for a buyout suitor waiting in the foyer IMO.
Not encouraging to see the medical officer depart. He may have been under pressure to resign because it looks like the failure blindsided them.
Looks like there at half of book value here. Over 100 million I'm cash. Marketcap at 50. Reducing work force by may 21st. Looks to be a clean up before a take out??
I will be buying on high volume close over the 10 DMA.
Huge gap upside to. Small outstanding to. Been adding on dips!
Any good news about the trials and the shorts get squeezed
By my take on book value, is currently trading at a 3rd of real value. Book value is $3 here.
Just a thought here but the reduction in work staff suggests potential interests or sale of the company. Could be a early groom position for merger also. With their balance sheet and potential pipeline, I think this gets bought up. Glta
Great call.held off till just now..96.
I'd wait til 90 cents
* * $IDRA Video Chart 04-07-2021 * *
Link to Video - click here to watch the technical chart video
Idera Pharmaceuticals Shares Continue Higher; Up 16%
Movers Trading Ideas
IDERA PHARMACEUTICALS ANNOUNCES RESULTS FROM ILLUMINATE-301 TRIAL OF TILSOTOLIMOD + IPILIMUMAB IN ANTI-PD-1 REFRACTORY ADVANCED MELANOMA
https://ir.iderapharma.com/news-releases/news-release-details/idera-pharmaceuticals-announces-results-illuminate-301-trial
Looking to buy around 1.45.after phase 3 failed.Was trading around 5.00+ or higher.Might have small rebound to 2.00
This pos didn't even bounce. What a waste of time this was
* * $IDRA Video Chart 03-19-2021 * *
Link to Video - click here to watch the technical chart video
Trades like a fat pos. Wonder if it moves.
Grabbed $1.93
Wow, really nice gain with twice the average volume! What happened?
Just In: $IDRA Idera Pharmaceuticals Announces Dan Soland to Join as Chief Operating Officer
– COO Role is Key to Preparedness for NDA Filing and Commercial Launch – – Clayton Fletcher , Head of Business Development & Strategic Planning , to Retire – EXTON, Pa., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Idera...
Find out more IDRA - Idera Pharmaceuticals Announces Dan Soland to Join as Chief Operating Officer
Just In: $IDRA Idera Pharmaceuticals to Present Tilsotolimod Data at ESMO Virtual Congress 2020
Final data from ILLUMINATE-204 trial in advanced melanoma and final results from ILLUMINATE-101 trial in refractory solid tumors to be presented AbbVie to present a trial-in-progress poster of ABBV-368 in combination with tilsotolimod in recurrent / metastatic head and neck squamous ce...
Find out more IDRA - Idera Pharmaceuticals to Present Tilsotolimod Data at ESMO Virtual Congress 2020
Nothing happening here except stock options being given to insiders
We need something positive to happen here
No, just waiting on news.
Anything new on idra today, looks like it had a decent day.
Well, looks like it's going to pop Monday morning. I'll be watching the pre market, just a little cautious here.
I owned IDRA some time ago (in part because of the BB position). Maybe I will give it another look.
That is very true, it is all about timing. Being there at the right time at the right place. Baker brothers have been here for a while, the company already has a good a pipeline of them being already in the phase 3, this stock use to be over a 1000 dollars at one point, I know, I use to follow it back in the day. The point is there was a volume spike after hours on Friday and that is on a Friday. I believe pillar is still buying shares, they know something is up, this kind of movement, generally tips of traders, I am inclined to believe we will hear some news in about 2 weeks time frame at the most.
Baker Brothers do indeed have a very good track record. However, it should be noted that they are patient long-term investors, not traders. It is worth following them long term, but one should not expect instant gratification when buying a Baker Brothers stock.
Whenever you see them on biotech almost a sure bet.
Thank you, I think I'll wait for the opening Monday before I make a decision
The Baker Brothers are very highly regarded hedge fund managers in the Biotech world. It should be noted they've held IDRA for a long time as have I. Their confidence was why I initially bought the stock. After the reverse split a couple years ago I took a chance and averaged down. Recently their data showed promising results. It's early stage data though. They've raised some money through private placements. That gives me faith they're on to something. If so with the small float this could really fly...of course it could be a dud too. That's the beauty of biotech...GLTA!
What does that mean?
Ah!!!! I see, baker brothers own this ticker too. It will be interesting to see what develops here.
If they have news next week then no, but if no news it might dip. This is when you say, I will take my chances either news or no news.
Is too late to buy?
Looks like IDRA could reach DVA*X market cap if any news in regards to COVID next week.
Over one million volume, something tells me data release next week.
You were right over $3.00 post market...only took three months!
Followers
|
122
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3443
|
Created
|
04/10/08
|
Type
|
Free
|
Moderators |
IDRA [NASD] https://www.otcmarkets.com/stock/IDRA/overview |
Idera Pharmaceuticals, Inc. |
We’re devoted to redefining the treatment of cancer and rare diseases where serious unmet needs exist.
https://www.iderapharma.com/our-company/
https://www.iderapharma.com/who-we-help/
https://www.iderapharma.com/our-approach/toll-like-receptor-immune-modulation/
Toll-like receptors (TLRs) are a class of proteins that are an important part of the innate immune system.
They alert the body to potential danger by recognizing pieces of bacteria, viruses, or damaged cells.
They essentially act like a smoke alarm, warning the body when trouble is detected.
Our lead investigational agent, tilsotolimod, activates TLR9. In cancer patients with solid tumors,
tilsotolimod is injected directly into a tumor to trigger TLR9 into action and prime a local immune response to help attack the tumor.
This has been demonstrated in pre-clinical models, and our translational studies during early clinical trials have shown rapid immune
activation in the injected tumor along with systemic increases in T cells.
Idera is investigating the combination of tilsotolimod with checkpoint inhibitors and other immune activators with the aim of providing improved outcomes for patients in need.
https://www.iderapharma.com/our-approach/key-publications/
https://www.iderapharma.com/areas-of-focus/oncology/immuno-oncology/
https://www.iderapharma.com/pipeline-programs/
TUMOR TYPE |
| |||||||
---|---|---|---|---|---|---|---|---|
Anti-PD-1 Refractory Advanced Melanoma |
| |||||||
Microsatellite-Stable Colorectal Cancer |
| |||||||
Resistant Solid Tumors |
| |||||||
Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma |
|
1 Tilsotolimod is an investigational agent which has not been approved by any regulatory authority
IDRA [NASD] |
Idera Pharmaceuticals, Inc. |
Healthcare | Biotechnology | USA |
Shs Outstand | 41.19M |
Shs Float | 38.72M ,
|
52W Range | 0.97 - 6.14 |
52W High | -81.76% |
Insider Own | 1.30% |
Inst Own | 19.70% |
Book/sh | 1.03 |
Cash/sh | 0.84 |
Employees | 32 |
Debt/Eq | 0.00 no short term either |
The Company has created DNA-based compounds that in preclinical studies act as antagonists of TLR7 and TLR9,
such as IMO-3100, or as antagonists of TLRs 7, 8, and 9, such as IMO-8400.
The Company is developing IMO-3100, an antagonist of TLR7 and TLR9, for the treatment of psoriasis.
It has selected IMO-8400, an antagonist of TLRs 7, 8, and 9, for development in the treatment of autoimmune diseases, with lupus as the initial disease indication.
IMO-2055, a TLR9 agonist, is its lead drug candidate for the treatment of cancer. Clinical trials of IMO-2055 completed by the Company
or by Merck KGaA include four Phase I clinical trials, of which two were in healthy subjects and two were in refractory cancer patients, and one Phase II clinical trial.
The Phase II clinical trial was a monotherapy trial of IMO-2055 in patients with metastatic or recurrent clear cell renal cancer.
In preclinical animal models, the Company TLR7, 8, and 9 agonists have shown adjuvant activity when combined with various types of antigens.
It has designed and created a new class of molecules to inhibit gene expression. These gene silencing oligonucleotides, which it refer to as GSOs,
are nucleic acid-based and represent a novel approach to selectively, silence gene expression.
It is actively engaged in preclinical research with its GSOs that is designed to explore their potential as research reagents and therapeutic agents.
In addition to the Company’s clinical programs in autoimmune and inflammatory diseases and in cancer,
it has identified TLR drug candidates for applications in the treatment of infectious diseases, respiratory diseases and hematological malignancies,
and TLR3 agonists for use as vaccine adjuvants.
IMO-2125, a synthetic DNA-based TLR9 agonist, is its lead candidate for the treatment of chronic hepatitis C virus (HCV), infection.
The Company conducted two Phase I clinical trials of IMO-2125 in patients with chronic HCV infection,
one in patients with HCV who had not responded to prior treatment and one in combination with ribavirin,
an antiviral medication approved for use in combination with interferon-alpha in the treatment of HCV infection, in treatment-naive patients with genotype 1 chronic HCV infection.
In addition to the use of TLR9 agonists in oncology applications, it selected IMO-4200 as a lead TLR7 and TLR8 agonist candidate for the treatment of hematological cancers.
Its TLR9 agonists are designed to induce immune responses that could be useful in restoring immune system balance. IMO-2134 is its lead TLR9 agonist for asthma and allergies.
In addition to use of TLR7, 8, and 9 agonists as vaccine adjuvants, it also has created TLR3 agonists for potential use as vaccine adjuvants.
The Company competes with Dynavax Technologies Corporation,
GlaxoSmithKline plc.,
Pfizer, Inc.,
VentiRx Pharmaceuticals.,
Novartis,
Dynavax Technologies Corporation,
VaxInnate, Inc.,
Intercell AG,
Cytos Biotechnology AG and
Celldex Therapeutics, Inc.
PER IHUB MGMT |
02-07-2021
DISCLAIMER: ONLY FOR MICK
https://investorshub.advfn.com/boards/profilea.aspx?user=1012
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION
AUTHORS MAY HAVE BUYS OR SELLS WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.
ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.Any
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |